Find insight on European pharmaceutical sector corporate bonds, GSK and more in the latest Market Talks covering Health Care.

GSK PLC closed 16.45% short of its 52-week high of £16.79, which the company reached on September 9th.

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine segment. See why the stock is a Buy.

GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Bank of America Securities reiterated a Sell ...

GSK PLC closed 15.77% below its 52-week high of £16.79, which the company reached on September 9th.

After years of underperformance relative to its peers and missing out on the lucrative market for the first set of COVID-19 vaccines, GSK has delivered a string of strong results. Sign up here.

GSK largely missed out on the lucrative market for COVID-19 vaccines, but has had a string of strong quarters after years of underperformance relative to its peers.

Moderna’s (MRNA) Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is shrinking. Read more here.

GSK (GSK) closed the latest trading day at $36.98, indicating a +0.65% change from the previous session's end. This change outpaced the S&P 500's 0.27% gain on the day. Elsewhere, the Dow gained 0 ...